Back from ASH 2025, Dr Suchitra Sundaram reports on notable frontline CLL data. Time‑limited pirtobrutinib combined with venetoclax and obinutuzumab produced high rates of undetectable minimal ...

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed ...

Jaypirca is approved for CLL/SLL patients previously treated with covalent BTK inhibitors, offering a new treatment option. The BRUIN-CLL-321 trial showed Jaypirca improved progression-free survival ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to living their lives to the fullest after being diagnosed with chronic ...

In an era dominated by social media, misinformation has become an all too familiar foe, infiltrating our feeds and sowing seeds of doubt and confusion. With more than half of social media users across ...

Please provide your email address to receive an email when new articles are posted on . Serious infections in patients with chronic lymphocytic leukemia have doubled despite increased use of ...

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

Venetoclax-based regimens showed a trend toward improved survival compared to BTK inhibitors, although subgroup sizes were small. Novel agents were associated with improved overall survival (OS) and ...

In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not associated with a reduced risk of serious infections requiring hospitalization, ...

Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...

Findings showed pirtobrutinib was noninferior to ibrutinib in both the pre-treated and intent-to-treat populations for the endpoint of ORR. Topline data were announced from a head-to-head phase 3 ...

Prompt recognition of autoimmune disease symptoms can help patients with chronic lymphocytic leukemia receive proper rheumatologic care. Immune dysregulation associated with chronic lymphocytic ...